ISMP
ISMP
Home Support ISMP Newsletters Webinars Report Errors Educational Store Consulting FAQ Tools About Us Contact Us
ISMP
ISMP
ISMP Facebook

TEXTBOOK AND PUBLICATION ERRATA

Correction Notice: Methylprednisolone Acetate Injection Monograph in Drug Facts & Comparisons

(08/19/2016)

Wolters Kluwer has issued a correction notice (www.wolterskluwercdi.com/clinical-notices/revisions/) for the Methylprednisolone Acetate Injection monograph in the Drug Facts & Comparisons database, available online and in the print publication Drug Facts and Comparisons, 2015 and 2016.

Information about off-label use and dosing of methylprednisolone acetate injection for Chronic Obstructive Pulmonary Disease (acute exacerbation) has been removed the Drug Facts & Comparisons database and Facts & Comparisons eAnswers but can still be found in the 2015 and 2016 bound version of Drug Facts & Comparisons.

The monograph previously read:

Indications
Off-label uses:
Chronic obstructive pulmonary disease (acute exacerbation) -

No cure currently exists for chronic obstructive pulmonary disease (COPD). Treatment strategies are aimed at minimizing the impact of current exacerbations and preventing development of subsequent exacerbations. Short-term treatment with oral corticosteroids has been shown to reduce recovery time, risk of early relapse, treatment failure, and length of hospital stay, as well as to improve lung function and arterial hypoxemia. However, long-term use is associated with significant adverse effects; recurrent courses should be avoided. (See Administration and Dosage.)29 ,30 ,31 ,32

Juvenile idiopathic arthritis (intra-articular) -

Data evaluating the safety and efficacy of methylprednisolone acetate intra-articular injections for the treatment of juvenile idiopathic arthritis (JIA) are limited and indicate that it is less effective than alternative agents. Intra-articular injections of corticosteroids are now generally considered to be a standard of care for JIA for select patient groups (uncomplicated monoarticular disease, oligoarticular disease), with data supporting triamcinolone hexacetonide as the preferred product because of its longer duration of effect. Currently, there are no national guidelines for the management of JIA. (See Administration and Dosage.)24 ,25 ,26 ,27 ,28

 

Administration & Dosage
Adult:
Off-label dosing:
Acute gout (off-label) -
0.5 to 2 mg/kg initially IM; may repeat as clinically indicated.15

Chronic obstructive pulmonary disease (acute exacerbation) (off-label) -
125 mg IV every 6 hours for 72 hours, then a tapered dose of oral prednisone on days 4 to 57.29 ,30 ,31 ,32

 

The monograph has been revised to read:

Indications
Off-label uses:
Juvenile idiopathic arthritis (intra-articular) -

Data evaluating the safety and efficacy of methylprednisolone acetate intra-articular injections for the treatment of juvenile idiopathic arthritis (JIA) are limited and indicate that it is less effective than alternative agents. Intra-articular injections of corticosteroids are now generally considered to be a standard of care for JIA for select patient groups (uncomplicated monoarticular disease, oligoarticular disease), with data supporting triamcinolone hexacetonide as the preferred product because of its longer duration of effect. Currently, there are no national guidelines for the management of JIA. (See Administration and Dosage.)24 ,25 ,26 ,27 ,28

 

Administration & Dosage
Adult:
Off-label dosing:
Acute gout (off-label) -
0.5 to 2 mg/kg initially IM; may repeat as clinically indicated.15





Home | Contact UsEmployment  | Legal Notices | Privacy Policy | Help Support ISMP
Med-ERRS Med-ERRS | MSOMedication Safety Officers Society | Consumer Medication SafetyFor consumers
 ISMP Canada ISMP Canada | ISMP Spain ISMP Spain | ISMP Brasil ISMP Brasil | International Group | Pennsylvania Patient Safety Authority

200 Lakeside Drive, Suite 200, Horsham, PA 19044, Phone: (215) 947-7797,  Fax: (215) 914-1492
© 2017 Institute for Safe Medication Practices. All rights reserved

 
ISMP
ISMP